About Precision Medicine & Genomics
Precision medicine uses genomic and other biological data to inform care. This sector covers sequencing, molecular diagnostics, pharmacogenomics and biomarkers, as well as the systems needed to connect test results with clinical decisions.
Precision medicine connects information about a person with decisions about their care. Genomics is one source of that information, alongside clinical history and other findings. The sector includes businesses that develop tests, laboratories that process samples and software that helps interpret the results. It also involves the healthcare teams responsible for explaining what a result means. A sequencing technology and a clinical service may use the same underlying science while serving different customers and requiring different kinds of support.
The journey from a sample to a useful result involves several steps. A laboratory performs the analysis, the findings are interpreted in context and a healthcare professional considers whether they are relevant to the question being asked. This creates roles for equipment suppliers, laboratory services, data specialists and clinical partners. It also explains why the cost of generating data is only one part of a service. Interpretation, communication and the ability to use a finding in care are part of the wider offering.
From a test to a decision
The investment questions extend beyond sequencing technology. They include clinical evidence, reimbursement, data governance and the ability to use a result in routine care. Laboratory networks, health systems and diagnostics businesses each play a part.
Pharmacogenomics is one example of how genomic information may inform care: it examines how genetic differences relate to a person’s response to medicines. Genomic information is considered alongside other relevant factors, rather than serving as a complete account of someone’s health. More broadly, test developers need to explain the intended use of a result and the evidence supporting it. A detailed report can still leave questions unanswered, and that uncertainty needs to be communicated clearly.
For a diagnostics business, adoption involves relationships as well as technology. Laboratories need dependable processes, healthcare teams need understandable reports and service providers need clear arrangements for data handling and clinical responsibility. Payment also has to fit the service being offered. These are practical areas for discussion at GLIF, where diagnostic developers, healthcare organisations and investors can explore what is needed to connect a useful test with the people and services able to use it.
Key Thematic Areas
- Whole genome and exome sequencing at population scale
- Polygenic risk scores in clinical pathways
- Pharmacogenomics and prescribing optimisation
- Circulating tumour DNA and molecular residual disease
- Multi-omics and biomarker discovery
- Clinical genomic data platforms and interoperability
Possible discussion formats
- Deal Room – proposed meetings between investors and relevant businesses or projects, subject to programme curation.
- Ministerial Roundtables – closed sessions on national genomic programmes and screening policy.
- Clinical Evidence Sessions – panels on what precision approaches have shown in practice and where evidence is thin.
- Regulatory & Data Governance Session – approval pathways, consent frameworks and cross-border genomic data transfer.
- Technology Showcase – demonstrations from sequencing, diagnostics and decision support companies.
Relevant Perspectives
- Health ministers and national genomic programme directors
- Clinical laboratory and pathology network operators
- Companion diagnostics and translational medicine teams
- Sequencing platform and molecular diagnostics companies
- Health technology assessment and reimbursement bodies
- Specialist diagnostics and life science tools investors
The Future of Precision Medicine Investment
- Market Development – which clinical needs a diagnostics business addresses and how demand can be assessed.
- Preventive Reimbursement – the evidence payers consider when evaluating screening and risk assessment.
- Genomic Capacity – the laboratories, data systems and expertise needed to deliver genomic services.
- Therapeutic Convergence – the relationship between targeted treatments and tests used to inform their use.
- Access Economics – how testing, interpretation and clinical delivery together affect affordability.
Questions to bring to GLIF
- When can a diagnostic test meaningfully change a treatment decision?
- What validation is needed across different patient populations?
- How might testing fit into clinical workflows and payment models?
Global Longevity Investors Forum (GLIF). A Global Investors Forum Platform.
This investment-sector topic connects to the five strategic tracks of the proposed GLIF programme. Explore the agenda for the current programme outline.
Explore the five strategic tracks
Further reading
Why attend
For diagnostic businesses
Show the problem your test or service addresses, and discuss how it could reach more providers.
For healthcare teams
Ask about evidence, cost, data handling and the work needed to use a new test in practice.
For investors
Discuss how a diagnostics business earns revenue, grows and supports better care decisions.
Explore at the forum
- Where can genetic information make a useful difference to a care decision?
- How can laboratories and healthcare providers work together?
- What does a testing business need to earn clinical and commercial trust?
Take part
- Explore precision health topics in the proposed programme.
- Enquire about demonstrating your work in the exhibition.
- Share your partnership or investment interests with the organising team.
Activities are planned. Access depends on your pass, selection where applicable and the final programme.
